—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Incyte Corporation (INCY) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for INCY, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.76 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How INCY has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.76 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Incyte Corporation moved 0.76% on average · correlation 0.21 · higher than 74% of US names
  • Beta, last 3 months 1.33 more rate-sensitive lately than over the year
  • On the 10 worst bond days −1.93% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.16% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against INCY on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Incyte Corporation

INCY in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Incyte develops and sells prescription medicines for blood cancers, certain solid tumours and inflammatory skin conditions, marketed mainly in the United States, Europe, Canada and Japan. Its lead product, Jakafi, treats myelofibrosis, polycythemia vera and a form of graft-versus-host disease, while other approved drugs address leukaemia, lymphoma and rare cancers. The company also runs a pipeline of experimental compounds for blood disorders, skin conditions and solid tumours, partly through collaborations with larger drugmakers such as Novartis and Lilly.
Where it sits in the stack
Incyte carries no seat in our index; it belongs to the healthcare sector of our universe, within biotechnology, where it counts as a commercial-stage drugmaker rather than an early pipeline name.
Who it is priced against
The diary has no peer group set for Incyte; a name the market compares it with is Bristol Myers Squibb, whose Inrebic competes with Jakafi in myelofibrosis.
Why Closelooknet tracks it
Incyte is an S&P 500 constituent; it does not yet carry a Closelooknet score, and the diary has not quoted it in any edition.
What the diary watches
Whether newer programmes in skin conditions such as atopic dermatitis and prurigo nodularis, or the ovarian cancer and solid tumour candidates, move from clinical stage toward approval.

Incyte Corporation (INCY) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Canaccord, 2026-08-20

The Street on this name

Analyst actions and the latest print for INCY from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Canaccord — target 152 Target set to $152 (+18.3% to spot) 2026-08-20

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Incyte Corporation (INCY)?

Incyte Corporation trades as INCY on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is INCY in a Closelooknet index?

Not currently — Incyte Corporation is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does INCY trade against its moving averages?

Uptrend stack intact: Trades +0.5% vs the 50-day and +16.6% vs the 200-day average, 6.6% below the 52-week high and +52.8% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Incyte Corporation trade when bond yields rise?

Over the past year Incyte Corporation had a beta of 0.76 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 74% of US names. On the 10 sessions in which long bonds fell most it moved −1.93% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Incyte Corporation do?

Incyte develops and sells prescription medicines for blood cancers, certain solid tumours and inflammatory skin conditions, marketed mainly in the United States, Europe, Canada and Japan. Its lead product, Jakafi, treats myelofibrosis, polycythemia vera and a form of graft-versus-host disease, while other approved drugs address leukaemia, lymphoma and rare cancers. The company also runs a pipeline of experimental compounds for blood disorders, skin conditions and solid tumours, partly through collaborations with larger drugmakers such as Novartis and Lilly. The diary has no peer group set for Incyte; a name the market compares it with is Bristol Myers Squibb, whose Inrebic competes with Jakafi in myelofibrosis.

Where does Incyte Corporation sit in the AI build-out?

Incyte carries no seat in our index; it belongs to the healthcare sector of our universe, within biotechnology, where it counts as a commercial-stage drugmaker rather than an early pipeline name. Incyte is an S&P 500 constituent; it does not yet carry a Closelooknet score, and the diary has not quoted it in any edition.

What has Wall Street done on Incyte Corporation recently?

The most recent analyst action on Incyte Corporation on the Closelooknet wire is a price target by Canaccord on 2026-08-20 (target 152). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for INCY, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.